Litigation Details for Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)
✉ Email this page to a colleague
Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-01-14 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 7,566,729; 7,635,707; 7,696,236; 7,767,225; 7,767,700; 7,816,383; 7,910,610; 7,988,994; 8,013,002; 8,084,475; 8,318,780; 8,383,150; 8,420,674; 8,592,462; 8,609,701; 8,648,098; 8,753,679; 8,754,109; 8,778,947 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Genentech, Inc. v. Aurobindo Pharma Limited
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-10-20 | 226 | Order - -Memorandum and Order | single term in U.S. Patent Nos. 7,566,729 (“the ’729 patent”), 7,635,707 (“the ’707 patent”), and 8,592,462… construction for a single term in U.S. Patent Nos. 7,566,729, 7,635,707, and 8,592,462. Plaintiffs'…the ‘729 patent, claims 2, 8, and 10 of the ‘707 patent, and claims 18 and 23 of the ‘462 patent. (D.I. … “It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification | External link to document |
| 2019-01-14 | 4 | B2; 7,696,236 B2; 7,767,700 B2; 8,420,674 B2; 7,566,729 B1; 7,635,707 B1; 8,592,462 B2; 8,609,701 B2; … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,767,225 B2; …January 2019 1:19-cv-00078-RGA 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
